ALCHEMIA LAUNCHES INTO INDIA

ALCHEMIA LAUNCHES INTO INDIA

BRISBANE drug development company Alchemia Limited (ASX: ACL) has launched a deep vein thrombosis prevention drug into India following success in the United States.

Fondaparinux is an injectable coagulant approved in the United States for the prevention and treatment of deep vein thrombosis after knee or hip surgery. It will be sold and marketed in India by international marketing partner Dr Reddy’s Laboratories Inc. under the name Fondared.

The drug is a generic version of GlaxoSmithKline’s Arixtra which achieved Indian sales of around $US2.7 million during the 2012 calendar year.

ACL expects to receive 25% of all profits from sales in India with the same economies from sales from any further territories outside the United States.

Dr Reddy’s Laboratories has filed a regulatory submission in Europe seeking marketing approval for the drug in key European markets.

CEO Charles Walker says the launch represents a milestone for the company.

“This launch represents the first for our fondaparinux outside of the U.S.,” he says.

“We look forward to fondaparinux’s expansion into additional territories.”

Meanwhile ACL’s pipeline of oncology products continues to develop.

The company recently announced the final recruitment of 390 patients for its most advanced cancer drug, HA-Irinotecan, which is in Phase III for the treatment of metastatic colorectal cancer.

The treatments are built on targeted cancer delivery which is used to selectively target cancer drugs to tumours.

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

REA Group buys full stake in end-to-end property sales interface Realtair

REA Group buys full stake in end-to-end property sales interface Realtair

Realestate.com.au operator REA Group (ASX: REA) has acquired the re...

HESTA to pump $250m into new global fund with Stafford Capital Partners

HESTA to pump $250m into new global fund with Stafford Capital Partners

Strong returns over the past three years from a $200 million global...

Pacific Smiles to extend nib dental offering to all centres

Pacific Smiles to extend nib dental offering to all centres

Takeover target Pacific Smiles (ASX: PSQ) may see its clinics filli...

The Chemist Warehouse deal is a sideshow: pharmacies are ripe for bigger disruption

The Chemist Warehouse deal is a sideshow: pharmacies are ripe for bigger disruption

There’s something curious about the proposed merger between C...